Zions Bancorporation N.A. Acquires 85 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Zions Bancorporation N.A. grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 55.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 239 shares of the medical research company’s stock after acquiring an additional 85 shares during the quarter. Zions Bancorporation N.A.’s holdings in IQVIA were worth $47,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Intech Investment Management LLC purchased a new stake in IQVIA during the third quarter valued at $223,000. Algert Global LLC bought a new position in shares of IQVIA in the 3rd quarter worth approximately $514,000. Larson Financial Group LLC boosted its holdings in shares of IQVIA by 745.1% in the third quarter. Larson Financial Group LLC now owns 431 shares of the medical research company’s stock worth $102,000 after buying an additional 380 shares during the last quarter. Fisher Asset Management LLC increased its holdings in IQVIA by 4.8% during the third quarter. Fisher Asset Management LLC now owns 7,398 shares of the medical research company’s stock valued at $1,753,000 after buying an additional 341 shares during the last quarter. Finally, Private Trust Co. NA boosted its stake in shares of IQVIA by 10.7% during the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock worth $115,000 after acquiring an additional 47 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Down 0.3 %

Shares of NYSE:IQV opened at $179.40 on Friday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The business’s 50 day moving average is $193.55 and its 200 day moving average is $206.91. The stock has a market cap of $31.63 billion, a P/E ratio of 23.92, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 52-week low of $176.74 and a 52-week high of $253.84.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on IQV shares. Citigroup decreased their target price on IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. UBS Group lowered their price objective on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Robert W. Baird reduced their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. JPMorgan Chase & Co. lowered their price target on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. Five investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average target price of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.